ATHA Key Statistics, Chart & Performance
The current stock price of ATHA is 6.75 USD. In the past month the price increased by 70.45%. In the past year, price increased by 19.45%.
ATHA Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to ATHA. When comparing the yearly performance of all stocks, ATHA is one of the better performing stocks in the market, outperforming 92.2% of all stocks.
ATHA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ATHA. ATHA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
ATHA Financial Highlights
Over the last trailing twelve months ATHA reported a non-GAAP Earnings per Share(EPS) of -9.68. The EPS increased by 66.04% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -125.61% | ||
| ROE | -140.83% | ||
| Debt/Equity | 0 |
ATHA Forecast & Estimates
7 analysts have analysed ATHA and the average price target is 4.08 USD. This implies a price decrease of -39.56% is expected in the next year compared to the current price of 6.75.
ATHA Ownership
ATHA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 47.22 | 981.68B | ||
| JNJ | JOHNSON & JOHNSON | 21.07 | 526.82B | ||
| MRK | MERCK & CO. INC. | 12.35 | 270.12B | ||
| PFE | PFIZER INC | 8.02 | 145.84B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.42 | 112.50B | ||
| ZTS | ZOETIS INC | 19.66 | 54.93B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.62 | 22.83B | ||
| VTRS | VIATRIS INC | 5.52 | 14.81B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 25.55 | 12.19B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.94B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.41B | ||
| GPCR | STRUCTURE THERAPEUTICS INC | N/A | 5.38B |
Related stock screener links
About ATHA
Company Profile
Athira Pharma, Inc. engages in the development of small molecules to restore neuronal health and stop neurodegeneration. The company is headquartered in Bothell, Washington and currently employs 26 full-time employees. The company went IPO on 2020-09-18. The firm is focused on developing small molecules to restore neuronal health and slow neurodegeneration. Its approach is designed to modulate the neurotrophic hepatocyte growth factor (HGF) system, which is critical to normal brain function. The Company’s lead drug candidate is ATH-1105. ATH-1105 is a novel, orally available, brain-penetrant small-molecule drug candidate designed to positively modulate the neurotrophic HGF system for the potential treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), Alzheimer’s disease (AD), and Parkinson’s disease (PD). ATH-1105 is in development for the potential treatment of ALS. Its ATH-1020 is a novel, orally available small molecule drug candidate designed to positively modulate the neurotrophic HGF system. The company has evaluated several other compounds in preclinical discovery and development for neurodegenerative diseases and other indications.
Company Info
ATHIRA PHARMA INC
18706 North Creek Parkway, Suite 104, Box 352141
Bothell WASHINGTON 98011 US
CEO: Leen Kawas
Employees: 26
Phone: 14256208501
ATHIRA PHARMA INC / ATHA FAQ
What does ATHA do?
Athira Pharma, Inc. engages in the development of small molecules to restore neuronal health and stop neurodegeneration. The company is headquartered in Bothell, Washington and currently employs 26 full-time employees. The company went IPO on 2020-09-18. The firm is focused on developing small molecules to restore neuronal health and slow neurodegeneration. Its approach is designed to modulate the neurotrophic hepatocyte growth factor (HGF) system, which is critical to normal brain function. The Company’s lead drug candidate is ATH-1105. ATH-1105 is a novel, orally available, brain-penetrant small-molecule drug candidate designed to positively modulate the neurotrophic HGF system for the potential treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), Alzheimer’s disease (AD), and Parkinson’s disease (PD). ATH-1105 is in development for the potential treatment of ALS. Its ATH-1020 is a novel, orally available small molecule drug candidate designed to positively modulate the neurotrophic HGF system. The company has evaluated several other compounds in preclinical discovery and development for neurodegenerative diseases and other indications.
Can you provide the latest stock price for ATHIRA PHARMA INC?
The current stock price of ATHA is 6.75 USD. The price decreased by -6.12% in the last trading session.
Does ATHIRA PHARMA INC pay dividends?
ATHA does not pay a dividend.
How is the ChartMill rating for ATHIRA PHARMA INC?
ATHA has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Where is ATHIRA PHARMA INC (ATHA) stock traded?
ATHA stock is listed on the Nasdaq exchange.
How many employees does ATHIRA PHARMA INC have?
ATHIRA PHARMA INC (ATHA) currently has 26 employees.
When does ATHIRA PHARMA INC (ATHA) report earnings?
ATHIRA PHARMA INC (ATHA) will report earnings on 2026-02-25, after the market close.